scholarly journals Asthma, Type 1 and Type 2 Diabetes Mellitus, and Inflammatory Bowel Disease amongst South Asian Immigrants to Canada and Their Children: A Population-Based Cohort Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0123599 ◽  
Author(s):  
Eric I. Benchimol ◽  
Douglas G. Manuel ◽  
Teresa To ◽  
David R. Mack ◽  
Geoffrey C. Nguyen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
South Asian ◽  
Population Based ◽  
Asian Immigrants ◽  
South Asian Immigrants ◽  
Inflammatory Bowel

Metformin Use Is Associated with a Lower Risk of Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus

2020 ◽  
Author(s):  
Chin-Hsiao Tseng
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
Type 2 Diabetes Mellitus ◽  
Bowel Disease ◽  
Cox Regression ◽  
Reference Group ◽  
Hazard Ratios ◽  
Inflammatory Bowel

Abstract Aim Our aim was to compare the risk of developing inflammatory bowel disease [IBD] between ever users and never users of metformin. Methods Patients with newly diagnosed type 2 diabetes mellitus from 1999 to 2005 were enrolled from Taiwan’s National Health Insurance. A total of 340 211 ever users and 24 478 never users who were free from IBD on January 1, 2006 were followed up until December 31, 2011. Hazard ratios were estimated by Cox regression incorporating the inverse probability of treatment weighting using a propensity score. Results New-onset IBD was diagnosed in 6466 ever users and 750 never users. The respective incidence rates were 412.0 and 741.3 per 100 000 person-years and the hazard ratio for ever vs never users was 0.55 [95% confidence interval: 0.51–0.60]. A dose–response pattern was observed while comparing the tertiles of cumulative duration of metformin therapy to never users. The respective hazard ratios for the first [<26.0 months], second [26.0–58.3 months] and third [>58.3 months] tertiles were 1.00 [0.93–1.09], 0.57 [0.52–0.62] and 0.24 [0.22–0.26]. While patients treated with oral antidiabetic drugs [OADs] without metformin were treated as a reference group, the hazard ratios for patients treated with OADs with metformin, with insulin without metformin [with/without other OADs] and with insulin and metformin [with/without other OADs] were 0.52 [0.42–0.66], 0.95 [0.76–1.20] and 0.50 [0.40–0.62], respectively. Conclusion A reduced risk of IBD is consistently observed in patients with type 2 diabetes mellitus who have been treated with metformin.

scholarly journals Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis

2020 ◽  
Vol 8 (1) ◽  
pp. e001220
Author(s):  
Jianhua Wu ◽  
Sarah L Mackie ◽  
Mar Pujades-Rodriguez
Keyword(s):  
Rheumatoid Arthritis ◽  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Population Based ◽  
Immune Mediated ◽  
Inflammatory Bowel ◽  
Dose Dependent

IntroductionIn immune-mediated inflammatory diseases, there is a lack of -estimates of glucocorticoid dose–response diabetes risk that consider changes in prescribed dose over time and disease activity.Research design and methodsPopulation-based longitudinal analysis of electronic health records from the UK Clinical Practice Research Datalink, linked to hospital admissions and the mortality registry (1998–2017). We included 100 722 adult patients without diabetes history, diagnosed with giant cell arteritis or polymyalgia rheumatica (n=32 593), inflammatory bowel disease (n=29 272), rheumatoid arthritis (n=28 365), vasculitis (n=6082), or systemic lupus erythematosus (n=4410). We estimated risks and HRs of type 2 diabetes associated with time-variant daily and total cumulative prednisolone-equivalent glucocorticoid dose using Cox regression methods.ResultsAverage patient age was 58.6 years, 65 469 (65.0%) were women and 8858 (22.6%) had a body mass index (BMI) ≥30 kg/m2. Overall, 8137 (8.1%) people developed type 2 diabetes after a median follow-up of 4.9 years. At 1 year, the cumulative risk of diabetes increased from 0.9% during periods of non-use to 5.0% when the daily prednisolone-equivalent dose was ≥25.0 mg. We found strong dose-dependent associations for all immune-mediated diseases, BMI levels and underlying disease duration, even after controlling for periods of active systemic inflammation. Adjusted HR for a <5.0 mg daily dose versus non-use was 1.90, 95% CI 1.44 to 2.50; range 1.70 for rheumatoid arthritis to 2.93 for inflammatory bowel disease.ConclusionsWe report dose-dependent risks of type 2 diabetes associated with glucocorticoid use for six common immune-mediated inflammatory diseases. These results underline the need for regular diabetic risk assessment and testing during glucocorticoid therapy in these patients.

1238-P: Developing a Culturally Tailored Social-Support Group Visit Model for South Asian Immigrants with Type 2 Diabetes in Atlanta

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1238-P
Author(s):  
MEGHA K. SHAH ◽  
NITHIN C. KURRA ◽  
MOHAMMED K. ALI ◽  
K.M. VENKAT NARAYAN
Keyword(s):  
Social Support ◽  
Type 2 Diabetes ◽  
South Asian ◽  
Support Group ◽  
Asian Immigrants ◽  
South Asian Immigrants ◽  
Group Visit ◽  
Culturally Tailored

scholarly journals Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links

BBA Clinical ◽  
2016 ◽  
Vol 5 ◽  
pp. 16-24 ◽  
Author(s):  
Abdo Jurjus ◽  
Assad Eid ◽  
Sahar Al Kattar ◽  
Marie Noel Zeenny ◽  
Alice Gerges-Geagea ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Colorectal Cancer ◽  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
Type 2 Diabetes Mellitus ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals Fermented Maillard Reaction Products by Lactobacillus gasseri 4M13 Alters the Intestinal Microbiota and Improves Dysfunction in Type 2 Diabetic Mice with Colitis

2021 ◽  
Vol 14 (4) ◽  
pp. 299
Author(s):  
Yu-Jin Jeong ◽  
Ho-Young Park ◽  
Han-Kyul Nam ◽  
Kwang-Won Lee
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Secretion ◽  
Bowel Disease ◽  
Function Type ◽  
Lactobacillus Gasseri ◽  
Inflammatory Bowel

Inflammatory bowel disease is a chronic relapsing disease. Multiple factors can cause inflammatory bowel disease (IBD), including diet, imbalance of the immune system, and impaired intestinal barrier function. Type 2 diabetes mellitus is a complex and chronic metabolic disease caused by a combination of insulin resistance and an ineffective insulin secretory response. The co-occurrence of these two diseases, demonstrating interrelated effects within the gut microbiota, has been frequently reported. This study evaluated the effects of a fermented glycated conjugate of whey protein and galactose with Lactobacillus gasseri 4M13 (FMRP) to prevent type 2 diabetes mellitus with inflammatory bowel disease. C57BLKS/J- db/db mice were orally administered FMRP for 14 consecutive days and 2% dextran sulfate sodium (DSS) in water ad libitum for 5 days to induce colitis. FMRP-fed mice showed improved insulin secretion and symptoms of colitis. Compared to the DSS group, the FMRP group showed a decreased abundance of six bacterial genera and increased abundance of Alistipes and Hungateiclostridium. In cecal contents, the levels of short-chain fatty acids increased in the FMRP group compared to those in the DSS group. Continuous administration of FMRP thus may improve the homeostasis of not only insulin secretion and inflammation, but also the intestinal environment in inflammatory bowel disease and type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document